rituximab IV 375 bendamustine 70 cytarabine 800 Mantle Cell Lymphoma Regimen Cycle 1 (CP-0398) Aug 2023
|
|
rituximab SC 1400 mg bendamustine 70 cytarabine 800 Mantle Cell Lymphoma Regimen Cycles 2-6 (CP-0399) Aug 2023
|
|
rituximab IV 375 bendamustine 90 Mantle Cell Lymphoma (R-Benda/R-Cytara) Regimen Cycle 1 (CP-0409) Oct 2022
|
|
rituximab IV 375 bendamustine 90 Mantle Cell Lymphoma (R-Benda/R-Cytara) Regimen Cycle 2 and 3 (CP-0410) Oct 2022
|
|
riTUXimab-hyaluronidase SC 1400 mg gemcitabine 1000 OXALIplatin 100 Regimen Cycles 2 -8 (CP-0408) September 2023
|
|
Ruxience (riTUXimab) IV 375 gemcitabine 1000 OXALIplatin Regimen (CP-0407) September 2023
|
|
methotrexate 20 mg Regimen (CP-0400) September 2023
|
|
Ruxeince (riTUXimab) 375 - idelalisib 150 mg Regimen Cycle 1 (CP-0442) Januray 2024
|
|
Ruxience (riTUXimab) 500 - idelalisib 150 mg Regimen Cycles 2-8 (CP-0443) January 2024
|
|
idelalisib 150 mg Regimen Cycles 9 + (CP-0444) January 2024
|
